A catalytic mechanism for caspase-1 and for bimodal inhibition of caspase-1 by activated aspartic ketones.
We have evaluated 619 aspartic ketones with 9 different types of prime-side groups (acyloxymethyl, aryloxymethyl, arylthiomethyl, alkylthiomethyl, acylamino-oxymethyl, sulfonylaminomethyl, alpha-ketoamide, alpha-(1-phenyl-3-trifluoromethyl-pyrazol-5-yl)oxymethyl (PTP), and aliphatic ketones) as inhibitors of caspase-1. The inhibitory behaviors could be classified as reversible, inactivating, or bimodal (i.e. reversible inhibition followed by slow inactivation) based on the kinetically observed formation of reversible thiohemiketal complexes and conversion to an irreversible thioether adduct, and the mechanism of any given ketone was only poorly predictable on the basis of leaving group structure and chemistry. Among 201 bimodal inhibitors, the rate of conversion of the reversible thiohemiketal complex to the inactive thioether (k(i)) was strictly first-order, consistent with direct conversion of the thiohemiketal to the thioether with no intermediate collapse to free ketone and thiolate. We have examined 22 crystallographic structures of caspase-1 complexed as a thiohemiketal with the inhibitors from 8 different ketone classes, and found the Cys285S-C-C(alpha)-leaving group dihedral angle to be near either to 60 degrees or to 180 degrees. Only the 180 degrees conformation was permissive for SN2 displacement of the leaving group and, furthermore, positioned His237Ndelta to stabilize developing charge on the leaving group. Among these structures and 19 additional complexes, all showed a strong interaction between His237Ndelta and the ketone or thiohemiketal oxygen. We therefore propose a proteolytic mechanism for caspase-1 involving polarization of the scissile carbonyl by the His237 imidazolium group. During thiohemiketal/thioether conversion (but probably not during peptide hydrolysis), the leaving group is stabilized by the His237 imidazolium.
Brady
K D
KD
BASF Bioresearch Corporation, Worcester, Massachusetts 01605-4314, USA. bradykd@basf.com
Giegel
D A
DA
Grinnell
C
C
Lunney
E
E
Talanian
R V
RV
Wong
W
W
Walker
N
N
D020170:Caspase 1 / Q000737:chemistry*; D061945:Caspase Inhibitors; D018360:Crystallography, X-Ray; D020128:Inhibitory Concentration 50; D007659:Ketones / Q000494:pharmacology*; D007700:Kinetics; D008956:Models, Chemical; D008958:Models, Molecular; D011725:Pyridines / Q000494:pharmacology; D013997:Time Factors
D061945:Caspase Inhibitors; D007659:Ketones; C120344:PD 177470; D011725:Pyridines; D020170:Caspase 1